<DOC>
	<DOCNO>NCT00003490</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . GM-CSF may make cancer cell sensitive effect chemotherapy . Combining one drug GM-CSF may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy , consist cyclophosphamide plus vincristine , follow GM-CSF treat patient multiple myeloma respond previous treatment .</brief_summary>
	<brief_title>Combination Chemotherapy Following GM-CSF Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate multiple myeloma patient treat cyclophosphamide vincristine cycling myeloma cell sargramostim ( GM-CSF ) . II . Evaluate whether Labelling Index ( LI ) change influence GM-CSF would predict group patient respond particular course specific design . III . Determine toxicity GM-CSF patient . OUTLINE : Patients receive subcutaneous injection sargramostim ( GM-CSF ) day 5 day . Two 3 day later , patient receive cyclophosphamide IV 30-45 minute day 1 , vincristine IV bolus day 8 , oral prednisone 4 time day day 1-4 . Patients also receive subcutaneous injection GM-CSF start day 2 continue 10 day neutrophil count least 1000/mm3 . Treatment continue every 3 week minimum 6 course absence disease progression unacceptable toxicity . Patients achieve least stable response receive GM-CSF 3 time week 2 year . Patients follow every 3-6 month . PROJECTED ACCRUAL : A maximum 30 patient accrue .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven multiple myeloma Pancytopenia relate multiple myeloma allow Failed progress least 2 chemotherapy biologic therapy regimens PATIENT CHARACTERISTICS : Age : 16 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Platelet count least 50,000/mm3 Absolute neutrophil count least 750/mm3 Hepatic : SGOT/SGPT le 3 time upper limit normal Bilirubin le 5.0 mg/dL Renal : Not specify Other : No active infection require intravenous antibiotic Not HIV positive Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics May fail prior bone marrow transplant No concurrent colony stimulate factor Concurrent immunoglobulin allow Chemotherapy : See Disease Characteristics Concurrent pamidronate allow Endocrine therapy : Not specify Radiotherapy : Concurrent standard radiation therapy treat extraskeletal and/or skeletal tumor site allow Surgery : Not specify Other : Concurrent epoetin alfa anemia allow</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2001</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>